Centene (NYSE:CNC) reported a significant GAAP loss for 2025 on Friday, as a massive $6.7 billion goodwill impairment charge overshadowed a 12% rise in total revenues.
However, the insurer issued a surprisingly robust 2026 outlook, signaling confidence that aggressive rate hikes and Medicaid cost controls will drive a sharp rebound in profitability.
For the full year 2025, the St. Louis-based healthcare giant posted a GAAP diluted loss of $(13.53) per share.
The nearly $7 billion non-cash impairment, recorded in the third quarter, was triggered by a "perfect storm" of a sliding stock price and the anticipated financial impact of the "One Big Beautiful Bill" Act, which introduced sweeping cuts to Medicaid and Affordable Care Act (ACA) funding.
Despite the paper loss, Centene’s adjusted earnings of $2.08 per share met the company's revised floor, supported by $174.6 billion in premium and service revenues.
The company’s 2026 guidance provided the primary catalyst for investor optimism.
Centene expects adjusted diluted EPS to jump to greater than $3, representing nearly 50% growth over 2025 levels.
Operationally, the focus remains on the Health Benefits Ratio (HBR)—the percentage of premiums spent on medical care.
Centene targets a consolidated HBR of 90.9% to 91.7% for 2026, a marked improvement from the 91.9% reported in 2025.
This improvement hinges on the company's ability to curb rising costs in behavioral health and specialty pharmaceuticals, which pressured margins throughout the past year.